Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRZA6G)

Drug Name

S-8921 Drug Info

Synonyms

S-8921; 151165-96-7; S 8921; CHEMBL18380; Methyl-1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate; AC1L4BG3; SCHEMBL1650817; DTXSID70164724; BDBM50085476; Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate; HY-19298; LS-193177; CS-0015040; methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylpentanoyl)-4-hydroxy-6,7,8-trimethoxynaphthalene-2-carboxylate; 2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Phase 2	[1]

Cross-matching ID

PubChem CID: 153965
CAS Number: CAS 151165-96-7
TTD Drug ID: DMRZA6G
VARIDT Drug ID: DR01061

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ileal sodium/bile acid cotransporter (SLC10A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odevixibat	DMYN391	Pruritus	EC90	Approved	[2]
Maralixibat	DMJCF1O	Pruritus	EC90	Approved	[2]
A-3309	DM4OHMP	Lipid metabolism disorder	5C52.Z	Phase 3	[3]
LUM001	DMQZXDW	Primary biliary cholangitis	DB96.1	Phase 2	[4]
264W94	DMBOL4K	Hyperlipidaemia	5C80	Phase 2	[5]
GSK2330672	DM4BTH8	Pruritus	EC90	Phase 2	[6]
Taurocholic Acid	DM2LZ8F	Type-2 diabetes	5A11	Phase 1/2	[7]
1614235 + 2330672	DMD751X	Type-2 diabetes	5A11	Phase 1	[8]
AZD-7806	DM34W56	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ileal sodium/bile acid cotransporter (SLC10A2)	TTPI1M5	NTCP2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
2	Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
3	Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
4	Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.
5	Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76.
6	Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
7	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960).